SLCO1B3

Across TCGA pan-cancer cohorts, SLCO1B3 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SLCO1B3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLCO1B3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLCO1B3 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

HNSC, LIHC, and COAD are the cancer types where SLCO1B3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLCO1B3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.635	<.001	12	view →
LIHC	Female	II,III,IV	−3.914	<.001	9	view →
COAD	Male	All	+1.516	<.001	8	view →
READ	All	All	+0.799	.004	6	view →
LUAD	All	All	+0.628	<.001	6	view →
STAD	All	All	+1.064	<.001	5	view →
CHOL	Female	All	−4.723	<.001	3	view →
ESCA	All	All	+1.579	.007	2	view →
LUSC	All	All	+0.543	<.001	2	view →
PRAD	All	All	+0.463	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SLCO1B3–HNSC

Open the HNSC breakdown →